Research programme: monoclonal antibodies - Viral Hemorrhagic Fever Consortium/Zalgen Labs

Alternative Names: Arevirumab 3

Latest Information Update: 16 Jun 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Viral Hemorrhagic Fever Consortium; Zalgen Labs
Developer Tulane University; University of Rochester; University of Texas Medical Branch; Zalgen Labs
Class Antivirals; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Lassa fever
Research Ebola virus infections; Lymphocytic choriomeningitis virus infections; Viral haemorrhagic fevers

Most Recent Events

05 Sep 2017 Zalgen Labs plans phase I trials in Lassa fever within three years
16 Jun 2017 Early research in Lymphocytic choriomeningitis virus infections in USA (Parenteral) before June 2017 (Zalgen labs pipeline, June 2017)
16 Jun 2017 Early research in Ebola virus infections in USA (Parenteral) before June 2017 (Zalgen labs pipeline, June 2017)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.